China based Sinovac Biotech (NASDAQ:SVA) has commenced Phase 3 trials its inactivated COVID-19 vaccine candidate, CoronaVac developed by Sinovac Life Sciences, in Turkey.
The trial will test efficacy and safety of CoronaVac and aims to be a pivotal study to support the licensure of this product.
In recent months, Phase 1/2 trials of CoronaVac in adults and elderly volunteers were conducted in China. The vaccine candidate was well tolerated for different dosage and no serious vaccine-related adverse events were reported.
Both seroconversion rates (generation of antibodies) were above 90%, indicating favorable immunogenicity.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.